Biomarker Study with Spatial Transcriptome, Tumor Immune Microenvironment and Microbiome Analysis in Induction Chemo-radiation Therapy Followed by Surgery with Perioperative Immunotherapy for Resectable Stage Discreate N2 IIIA-B Non-small Cell Lung Cancer (SQUAT-TR1 Study) (WJOG12119LTR1)

Biomarker Study with Spatial Transcriptome, Tumor Immune Microenvironment and Microbiome Analysis in Induction Chemo-radiation Therapy Followed by Surgery with Perioperative Immunotherapy for Resectable Stage Discreate N2 IIIA-B Non-small Cell Lung Cancer (SQUAT-TR1 Study) (WJOG12119LTR1) - WJOG12119LTR1: SQUAT-TR1 study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058336

Enrollment

Registered

2025-07-01

Start date

2026-06-18

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were enrolled in WJOG12119L and, at the time of enrollment in the present study, had not withdrawn their informed consent for that trial.

Exclusion criteria

Exclusion criteria: Patients deemed inappropriate for inclusion by the attending physician.

Design outcomes

Primary

Measure	Time frame
Association between the major pathological response (MPR) rate and biomarkers identified through tumor microenvironment and microbiome analyses	—

Countries

Japan

Contacts

Public ContactNaoki Ishizuka

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results